CASI Pharmaceuticals Inc ( CASI ):
* CASI PHARMACEUTICALS ANNOUNCES PLAN TO SUBMIT IND
APPLICATION
FOR CID-103, AN ANTI-CD 38 ANTIBODY IN ANTIBODY-MEDIATED
REJECTION, AND RECEIPT OF A NON-BINDING PROPOSAL TO ACQUIRE
ENTIRE CHINA BUSINESS OF THE COMPANY
* CASI PHARMACEUTICALS INC ( CASI ) - TO SUBMIT IND APPLICATION FOR
CID-103
BY END OF 2024
* CASI PHARMACEUTICALS INC ( CASI ) - BOARD GOT A PRELIMINARY
NON-BINDING
PROPOSAL LETTER DATED JUNE 21, FROM WEI-WU HE, CHAIRMAN OF BOARD
AND CEO OF COMPANY
* CASI PHARMACEUTICALS INC ( CASI ) - PROPOSED DEAL FOR PURCHASE
PRICE OF
$40.0 MILLION, WHICH SHALL INCLUDE ASSUMPTION OF UP TO $20.0
MILLION OF INDEBTEDNESS OF COMPANY
Source text for Eikon:
Further company coverage: